Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tislelizumab”

538 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 538 results

Testing effectiveness (Phase 2)Study completedNCT05086627
What this trial is testing

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital 118
Large-scale testing (Phase 3)Study completedNCT03957590
What this trial is testing

Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
BeiGene 370
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06396585
What this trial is testing

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Who this might be right for
Immunotherapy Gastroesophageal Junction
Fujian Cancer Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06728618
What this trial is testing

Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma

Who this might be right for
Oral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell Carcinoma+1 more
Shanghai Zhongshan Hospital
Large-scale testing (Phase 3)Ended earlyNCT04866017
What this trial is testing

Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
BeiGene 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT05609370
What this trial is testing

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Who this might be right for
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
BeiGene 113
Early research (Phase 1)Study completedNCT04047862
What this trial is testing

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Locally Advanced and Metastatic Solid Tumors
BeiGene 446
Testing effectiveness (Phase 2)Looking for participantsNCT06856837
What this trial is testing

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Who this might be right for
Metastatic Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 140
Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Testing effectiveness (Phase 2)UnknownNCT05278351
What this trial is testing

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Who this might be right for
Colorectal Neoplasms Malignant
Shanghai Zhongshan Hospital 87
Testing effectiveness (Phase 2)UnknownNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06323369
What this trial is testing

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 154
Large-scale testing (Phase 3)UnknownNCT05910970
What this trial is testing

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Who this might be right for
Hepatocellular CarcinomaRecurrenceImmune Checkpoint Inhibitor
Guangxi Medical University 200
Testing effectiveness (Phase 2)UnknownNCT04902261
What this trial is testing

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Who this might be right for
Recurrent Pancreatic Cancer
Changhai Hospital 140
Early research (Phase 1)Ended earlyNCT05904496
What this trial is testing

BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
BeiGene 44
Testing effectiveness (Phase 2)UnknownNCT05143099
What this trial is testing

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

Who this might be right for
Colorectal Neoplasms
Shanghai Zhongshan Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT07109401
What this trial is testing

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

Who this might be right for
Perioperative ImmunotherapyLimited Stage Lung Small Cell CarcinomaResectable Small Cell Lung Cancer
Fudan University 37
Early research (Phase 1)Active Not RecruitingNCT05167071
What this trial is testing

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Who this might be right for
Solid TumorsNeuroendocrine TumorsCRC
Harbour BioMed (Guangzhou) Co. Ltd. 53
Testing effectiveness (Phase 2)UnknownNCT04652492
What this trial is testing

Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Zhongda Hospital 72
Not applicableUnknownNCT05546619
What this trial is testing

Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection

Who this might be right for
Hepatocellular Carcinoma
Sulai Liu 30
Load More Results
28